<i>FLT3</i> -ITD measurable residual disease from the QuANTUM-First trial

Mark J. Levis, Harry P. Erba, Pau Montesinos, Hee-Je Kim, Radovan Vrhovac, Elżbieta Patkowska, Pavel Žák, Po-Nan Wang, Jaime E. Connolly Rohrbach, Ken C. N. Chang, Li Liu, Yasser Mostafa Kamel, Karima Imadalou, Arnaud Lesegretain, Jorge Cortes, Mikkael A. Sekeres, Hervé Dombret, Sergio Amadori, Jianxiang Wang, Richard F. Schlenk, Alexander E. Perl

Open source

DOI: 10.1182/bloodadvances.2025016444
Published: 2026-02-10
Container: Blood Advances
Publisher: American Society of Hematology
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1182/bloodadvances.2025016444,
  title = {<i>FLT3</i>
                    -ITD measurable residual disease from the QuANTUM-First trial},
  author = {Mark J. Levis and Harry P. Erba and Pau Montesinos and Hee-Je Kim and Radovan Vrhovac and Elżbieta Patkowska and Pavel Žák and Po-Nan Wang and Jaime E. Connolly Rohrbach and Ken C. N. Chang and Li Liu and Yasser Mostafa Kamel and Karima Imadalou and Arnaud Lesegretain and Jorge Cortes and Mikkael A. Sekeres and Hervé Dombret and Sergio Amadori and Jianxiang Wang and Richard F. Schlenk and Alexander E. Perl},
  year = {2026},
  journal = {Blood Advances},
  doi = {10.1182/bloodadvances.2025016444},
  url = {https://doi.org/10.1182/bloodadvances.2025016444}
}

RIS

TY  - JOUR
TI  - <i>FLT3</i>
                    -ITD measurable residual disease from the QuANTUM-First trial
AU  - Mark J. Levis
AU  - Harry P. Erba
AU  - Pau Montesinos
AU  - Hee-Je Kim
AU  - Radovan Vrhovac
AU  - Elżbieta Patkowska
AU  - Pavel Žák
AU  - Po-Nan Wang
AU  - Jaime E. Connolly Rohrbach
AU  - Ken C. N. Chang
AU  - Li Liu
AU  - Yasser Mostafa Kamel
AU  - Karima Imadalou
AU  - Arnaud Lesegretain
AU  - Jorge Cortes
AU  - Mikkael A. Sekeres
AU  - Hervé Dombret
AU  - Sergio Amadori
AU  - Jianxiang Wang
AU  - Richard F. Schlenk
AU  - Alexander E. Perl
PY  - 2026
JO  - Blood Advances
DO  - 10.1182/bloodadvances.2025016444
UR  - https://doi.org/10.1182/bloodadvances.2025016444
ER  -

APA

Levis, M. J., Erba, H. P., Montesinos, P., Kim, H., Vrhovac, R., Patkowska, E., Žák, P., Wang, P., Rohrbach, J. E. C., Chang, K. C. N., Liu, L., Kamel, Y. M., Imadalou, K., Lesegretain, A., Cortes, J., Sekeres, M. A., Dombret, H., Amadori, S., Wang, J., Schlenk, R. F., & Perl, A. E. (2026). <i>FLT3</i> -ITD measurable residual disease from the QuANTUM-First trial. Blood Advances. https://doi.org/10.1182/bloodadvances.2025016444

Source records

crossref · retrieved 2026-09-25T22:26:24.772Z